Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Nicole M. Panhuyzen-Goedkoop
Dr. Erik Ekker Solberg,
An Echo Screening Tool for Sudden Cardiac Death in Young Athletes M.A. Grenier et al.Presentation Abstract, 23rd Annual American Society of Echocardiography Meeting; Cincinnati, Ohio, USA: 30 June–3 July
85 athletes, 14-19 years old, underwent pre-participation cardiovascular screening (PPS) including a limited echocardiography (nine minutes recording, off-line interpretation done separately) with real-time qualitative interpretation of a 15 image protocol. Those with an abnormal outcome were referred for a standard echocardiography. Although their standard PPS was normal, 10 athletes (12%) had an abnormal outcome of the real-time 15 image echocardiography study: dilated aortic root in 4, PDA in 1, ASD in 1, LV dysfunction (EF 48%) in 1, LV noncompaction in 2, and LVH in 1 athlete. The authors revealed a high rate of clinically silent cardiovascular disease, with an unknown impact of early identification, intervention strategies and the risk of undetecting the disease.
This is an interesting study testing simplification of the screening process. Rapid interpretation of limited echocardiography, however, may lead to misinterpretation of the data. It was remarkable that in those athletes with an abnormal echocardiography study (12%), none had an abnormal ECG, while several of the abnormalities described are usually associated with abnormal ECG findings. The identified diseases in this study are not always silent diseases at high risk for SCD. And left ventricular dysfunction based on ejection fraction of 48% alone does not imply pathology in an athlete in a position to succumb to bradycardia. Therefore not all athletes in this study with identified pathology have to be excluded from participation in sports.
It is valuable that the worth of limited echo in PPS is tested. However it is not time to change the existent practice.
© 2017 European Society of Cardiology. All rights reserved